Építés alatt – nem éles oldal
Belépés
Toborzás még nem indultFázis nélkül

Impact of Radiotherapy-Immunotherapy Timing in NSCLC Brain Metastases

A legfontosabb adatok

Ki végzi
Xiangya Hospital of Central South University
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
150 fő, tervezett
Kezdés
2026. jún. 5.
Várható befejezés
2030. jún. 1.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • Brain radiotherapy
A regiszteradat frissítve
2026. június 10.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with non-small cell lung cancer (NSCLC) that has spread to the brain. They must already be planned to get radiotherapy together with a PD-1/PD-L1 inhibitor as part of their usual care.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
NSCLC confirmed by tissue or cell tests, with brain metastases (spread to the brain) seen on a contrast MRI of the head. ECOG Performance Status 0-2, meaning people who are up and about and can care for themselves. Expected to live at least 3 months.
Korábbi kezelés
Must be scheduled for radiotherapy combined with a PD-1/PD-L1 inhibitor. People whose tumour has a driver gene mutation must have already had targeted therapy that stopped working. Cannot join after earlier whole-brain radiotherapy, stereotactic radiotherapy for brain metastases, or brain surgery.
Biomarker vagy leletérték
No driver gene mutation, or a driver gene mutation with documented failure of earlier targeted therapy.

A részvétel fő kizáró okai

  • Earlier whole-brain radiotherapy, stereotactic radiotherapy for brain metastases, or brain surgery
  • Cannot have MRI or cannot tolerate gadolinium contrast dye (for example severe liver or kidney failure)
  • Active autoimmune disease needing whole-body treatment, or long-term high-dose drugs that suppress the immune system
  • Pregnant or breastfeeding women
  • Other serious problems that, in the investigator's view, mean the person cannot take part

A regiszter feltételei, szó szerint

Mind a 11 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥ 18 years; no gender restriction
  • Histologically or cytologically confirmed NSCLC, with brain metastases confirmed by contrast-enhanced cranial MRI
  • Scheduled to receive radiotherapy combined with a PD-1/PD-L1 inhibitor, in accordance with real-world clinical treatment plans
  • Negative for driver gene mutations, or positive for mutations but with documented failure of prior targeted therapy
  • ECOG Performance Status score of 0-2, with an estimated life expectancy of ≥ 3 months
  • Voluntarily signs the informed consent form and agrees to cooperate with blood/imaging data collection and follow-up procedures

Ki nem vehet részt

  • History of whole-brain radiotherapy, stereotactic radiotherapy for brain metastases, or brain surgery
  • Presence of contraindications to MRI or inability to tolerate gadolinium-based contrast agents (e.g., severe hepatic or renal insufficiency)
  • Presence of active autoimmune disease requiring systemic treatment, or requirement for long-term use of high-dose immunosuppressive agents
  • Pregnant or lactating women
  • Other circumstances deemed by the investigator to involve severe complications or render the patient unsuitable for enrollment

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this observational study is to learn about the effects of the timing of radiation therapy and immunotherapy in adults with non-small cell lung cancer (NSCLC) that has spread to the brain. The main questions it aims to answer are:

A teljes eredeti leírásKevesebb

1. Does the timing of the two treatments change how long the brain tumor stays stable and how long participants live? 2. What medical problems do participants have when receiving these treatments at different times? 3. How does the timing of treatments affect the body's immune system?

Researchers will compare participants who receive radiation and immunotherapy 30 days or less apart to those who receive them more than 30 days apart to see if the timing affects the treatment's success and safety.

Participants already receiving radiation and immunotherapy as part of their regular medical care will:

1. Allow researchers to collect information about their treatment, health, and medical imaging during regular checkups. 2. Give a small blood sample during their routine blood draws. 3. Have standard magnetic resonance imaging (MRI) scans of their brain.

A vizsgálat csoportja

  • Non-small cell lung cancer brain metastases

    This cohort comprises adult patients (aged 18 years and older) with histologically or cytologically confirmed (NSCLC who have brain metastases confirmed by contrast-enhanced head MRI. Participants in this cohort are scheduled to receive standard-of-care radiotherapy combined with PD-1/PD-L1 immune checkpoint inhibitors based on real-world clinical treatment plans. Eligible participants must have an ECOG performance status of 0 to 2, an expected survival of at least 3 months, and be either driver-gene negative or have experienced disease progression following prior targeted therapies. The cohort strictly excludes patients who have a history of WBRT, SRS for brain metastases, or brain surgery. Additionally, individuals with contraindications to MRI (or intolerance to gadolinium contrast agents), active autoimmune diseases requiring systemic treatment or long-term high-dose immunosuppressants, and pregnant or lactating women are excluded.

    Kezelés: Brain radiotherapy

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Immune Microenvironment-driven Radiotherapy-immunotherapy Combined With Time-series Strategy for NSCLC Brain Metastases: an Exploratory Study Based on a Clinical Cohort.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. június 10.